Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10526309 | 0.77 | KDM1A (0.46) | KMT2AOPRM1 | |
| SCHEMBL923226 | 0.77 | KMT2A (0.45) | KMT2AOPRM1CA12CA1CA2 | |
| SCHEMBL1008115 | 0.77 | KMT2A (0.45) | KMT2AOPRM1CA12CA1CA2 | |
| SCHEMBL10529080 | 0.77 | KMT2A (0.45) | KMT2AOPRM1CA12CA1CA2 | |
| SCHEMBL1986488 | 0.77 | KMT2A (0.49) | KMT2AOPRM1OPRL1OPRD1 | |
| SCHEMBL2816850 | 0.77 | KMT2A (0.45) | KMT2AOPRM1CA12CA1CA2 | |
| SCHEMBL3206919 | 0.77 | KMT2A (0.45) | KMT2AOPRM1CA12CA1CA2 | |
| SCHEMBL4437271 | 0.77 | KDM1A (0.50) | KMT2AOPRM1OPRL1 | |
| SCHEMBL1007128 | 0.77 | KMT2A (0.78) | KMT2AOPRM1OPRL1OPRD1 | |
| SCHEMBL12284174 | 0.75 | OPRM1 (0.46) | KMT2AOPRM1CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009073300-A1 | [1H- PYRAZOLO [3, 4-B] PYRIDINE-4-YL] -PHENYLE OR -PYRIDIN-2-YLE DERIVATIVES AS PROTEIN KINASE C-THETA | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-11 | — | — | WO | disclosed |